Skip to main content
Premium Trial:

Request an Annual Quote

After Snags, Bio-Rad Closes Acquisition of Ciphergen's Proteomics Tools Division

NEW YORK (GenomeWeb News) - Bio-Rad Laboratories has finalized its purchase of Ciphergen Biosystems’ proteomics tools business, the company said today.
 
The companies had expected the deal, which was announced in August, to close November 1, but it was delayed for undisclosed reasons after receiving shareholder approval in late October.
 
Bio-Rad paid Ciphergen $20 million in cash and made a $3 million equity investment in the company to purchase its ProteinChip business and worldwide technology rights to its Surface Enhanced Laser Desorption Ionization (SELDI) technology. Also included in the agreement are “certain product lines,” manufacturing capability, intellectual property, and rights to Ciphergen’s established customer base.
 
Bio-Rad CEO Norman Schwartz said in a statement that the acquisition of Ciphergen’s tools for protein profiling and biomarker discovery will enable the company to “offer a more complete range of tools of proteomics workflows.”
 
Last week, Ciphergen posted a 34-percent drop in third-quarter revenue while Bio-Rad saw an 8-percent increase in revenues for the quarter, during which it also acquired quality control products maker Blackhawk Biosystems for an undisclosed amount.
The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.